NEUDOPA
Generic Name: Carbidopa + Levodopa Tabs 25mg + 250mg
Packing: 10 x 10
Registration # 39710
Description
NEUDOPA is a combination of carbidopa, U.S.P., an aromatic amino acid decarboxylase inhibitor, and levodopa, U.S.P., the metabolic precursor of dopamine, for use in the treatment of Parkinson’s disease and syndrome.
Levodopa relieves the symptoms of Parkinson’s disease by being decarboxylated to dopamine in the brain. Carbidopa, which does not-cross the blood-brain barrier, inhibits the extracerebal decarboxylation of levodopa, making more levodopa available for transport to the brain and subsequent conversion to dopamine.
NEUDOPA improves overall therapeutic response as compared to levodopa.
NEUDOPA provides effective long -lasting levodopa plasma levels at doses that are approximately 80 percent lower than those needed with levodopa alone. While pyridoxine hydrochloride (Vitamin B6) is known to accelerate the peripheral metabolism of levodopa to dopamine, carbidopa prevents this action.
Uses / Indications
Levodopa + Carbidopa (NEUDOPA) is indicated for the treatment of Parkinson’s disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. Levodopa + Carbidopa (NEUDOPA) frequently is helpful in the management of tremor, dysphagia, sialorrhea, and postural instability associated with Parkinson’s disease and syndrome.
When therapeutic response to levodopa alone is irregular, and signs and symptoms of Parkinson’s disease are not evenly controlled throughout the day, substitution of Levodopa + Carbidopa (NEUDOPA) usually is effective in reducing fluctuations in response. By reducing certain adverse reactions produced by levodopa alone, Levodopa + Carbidopa (NEUDOPA) permits more patients to obtain adequate relief of the symptoms of Parkinson’s disease.
Levodopa + Carbidopa (NEUDOPA) is also indicated for patients with Parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (Vitamin B6).Nimesulide (Modact-IR) is indicated in the treatment of acute pain and primary dysmenorrhoea. Nimesulide should only be prescribed as second line treatment. The decision to prescribed nimesulide should be based on assesment of the individual patient’s overall risks.
NEUDOPA is a combination of carbidopa, U.S.P., an aromatic amino acid decarboxylase inhibitor, and levodopa, U.S.P., the metabolic precursor of dopamine, for use in the treatment of Parkinson’s disease and syndrome.
Levodopa relieves the symptoms of Parkinson’s disease by being decarboxylated to dopamine in the brain. Carbidopa, which does not-cross the blood-brain barrier, inhibits the extracerebal decarboxylation of levodopa, making more levodopa available for transport to the brain and subsequent conversion to dopamine.
NEUDOPA improves overall therapeutic response as compared to levodopa.
NEUDOPA provides effective long -lasting levodopa plasma levels at doses that are approximately 80 percent lower than those needed with levodopa alone. While pyridoxine hydrochloride (Vitamin B6) is known to accelerate the peripheral metabolism of levodopa to dopamine, carbidopa prevents this action.
